Agilon Health, Inc. (AGL) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $92.73 (-3.90%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 9, 2026 | George Hill | Deutsche Bank | $33.00 | -64.4% |
| Aug 15, 2025 | Jack Slevin | Jefferies | $27.50 | -70.3% |
| Oct 29, 2024 | Daniel Grosslight | Citigroup | $62.50 | -32.6% |
| Oct 2, 2024 | Adam Ron | Bank of America Securities | $75.00 | -19.1% |
| Aug 8, 2024 | George Hill | Deutsche Bank | $100.00 | +7.8% |
| May 29, 2024 | Michael Ha | Robert W. Baird | $150.00 | +61.8% |
| May 24, 2024 | Jailendra Singh | Truist Financial | $162.50 | +75.2% |
| Jul 26, 2022 | David MacDonald | Truist Financial | $825.00 | +789.7% |
Top Analysts Covering AGL
AGL vs Sector & Market
| Metric | AGL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.80 | 2.25 | 2.42 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | -27.8% | +16316.2% | +17.1% |
| P/E Ratio | -1.18 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.29B | $1.35B | $1.44B | 4 |
| 2026-12-31 | $5.42B | $5.46B | $5.49B | 12 |
| 2027-03-31 | $1.35B | $1.41B | $1.51B | 5 |
| 2027-06-30 | $1.35B | $1.42B | $1.51B | 5 |
| 2027-09-30 | $1.37B | $1.44B | $1.54B | 5 |
| 2027-12-31 | $1.41B | $1.48B | $1.59B | 5 |
| 2028-03-31 | $1.56B | $1.64B | $1.75B | 4 |
| 2028-06-30 | $1.54B | $1.61B | $1.73B | 4 |
| 2028-09-30 | $1.55B | $1.62B | $1.73B | 4 |
| 2028-12-31 | $1.54B | $1.61B | $1.73B | 4 |
| 2029-12-31 | $6.57B | $6.79B | $7.04B | 3 |
| 2030-12-31 | $7.17B | $7.41B | $7.68B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.84 | $-1.69 | $-1.59 | 3 |
| 2026-12-31 | $-8.84 | $-5.38 | $-3.81 | 9 |
| 2027-03-31 | $0.34 | $0.36 | $0.39 | 3 |
| 2027-06-30 | $-0.89 | $-0.82 | $-0.77 | 5 |
| 2027-09-30 | $-0.85 | $-0.78 | $-0.73 | 3 |
| 2027-12-31 | $-3.11 | $-2.85 | $-2.68 | 6 |
| 2028-03-31 | $0.75 | $0.80 | $0.88 | 4 |
| 2028-06-30 | $0.22 | $0.23 | $0.25 | 6 |
| 2028-09-30 | $0.29 | $0.31 | $0.34 | 4 |
| 2028-12-31 | $0.09 | $0.09 | $0.10 | 7 |
| 2029-12-31 | $-1.74 | $-1.66 | $-1.59 | 4 |
| 2030-12-31 | $-0.38 | $-0.36 | $-0.35 | 2 |
Frequently Asked Questions
What is the analyst consensus for AGL?
The consensus among 15 analysts covering Agilon Health, Inc. (AGL) is Hold with an average price target of $46.25.
What is the highest price target for AGL?
The highest price target for AGL is $825.00, set by David MacDonald at Truist Financial on 2022-07-26.
What is the lowest price target for AGL?
The lowest price target for AGL is $27.50, set by Jack Slevin at Jefferies on 2025-08-15.
How many analysts cover AGL?
15 analysts have issued ratings for Agilon Health, Inc. in the past 12 months.
Is AGL a buy or sell right now?
Based on 15 analyst ratings, AGL has a consensus rating of Hold (2.80/5) with a -27.8% upside to the consensus target of $46.25.
What are the earnings estimates for AGL?
Analysts estimate AGL will report EPS of $-1.69 for the period ending 2026-09-30, with revenue estimated at $1.35B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.